Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Le Malicot, K
Di Fiore, F
Valle, Juan W
AffiliationDepartment of Digestive Oncology, Burgundy Franche-Conte University, University hospital Dijon, Dijon, France
MetadataShow full item record
AbstractPatients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
CitationEvaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. 2017, 49(5):568-571 Dig Liver Dis
JournalDigestive and Liver Disease